The studies revealed that targeted blockade of CD73 can enhance the therapeutic activity of anti-PD-1 and anti-CTLA-4 monoclonal antibodies and may thus potentiate therapeutic strategies targeting ICIs for colorectal cancer, breast cancer, and prostate cancer (126, 135). The gene discussed is NT5E; the disease is breast carcinoma.